Pfizer & #039;s TALZENNA ® in combination with XTANDI® receives U.S. FDA approval
Pfizer (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has approved TALZENNA (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI (enzalutamide), for the treatment of adult patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC).
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news
More News: Cancer | Cancer & Oncology | Food and Drug Administration (FDA) | Gastroschisis Repair | Genetics | Oral Cancer | Pfizer | Pharmaceuticals | Prostate Cancer